Aberrant expression of the oncogenic transcription factor FOXP1 is a common feature of diffuse large B-cell lymphoma (DLBCL). We have combined chromatin immunoprecipitation and gene expression profiling after FOXP1 depletion with functional screening to identify targets of FOXP1 contributing to tumor cell survival. We find that the sphingosine-1-phosphate receptor 2 (S1PR2) is repressed by FOXP1 in activated B-cell (ABC) and germinal center B-cell (GCB) DLBCL cell lines with aberrantly high FOXP1 levels; S1PR2 expression is further inversely correlated with FOXP1 expression in three patient cohorts. Ectopic expression of wild type S1PR2, but not of a point mutant incapable of activating downstream signaling pathways, induces apoptosis in DLBCL cells and restricts tumor growth in subcutaneous and orthotopic models of the disease. The pro-apoptotic effects of S1PR2 are phenocopied by ectopic expression of the small G-protein G13, but are independent of AKT signaling. We further show that low S1PR2 expression is a strong negative prognosticator of patient survival, alone and especially in combination with high FOXP1 expression. The S1PR2 locus has previously been demonstrated to be recurrently mutated in GCB DLBCL; the transcriptional silencing of S1PR2 by FOXP1 represents an alternative mechanism leading to inactivation of this important hematopoietic tumor suppressor. (2016). The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling. Blood, 127(11):
Introduction
The forkhead box protein 1 (FOXP1) transcription factor is aberrantly expressed in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) and represents a widely accepted biomarker for survival prognostication in DLBCL. The FOXP1 genomic locus is recurrently targeted by genomic rearrangements in ABC DLBCL as well as in marginal zone lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT) and in chronic lymphocytic leukemia, which correlates with a poor prognosis in each disease entity. [1] [2] [3] Primary FOXP1 translocations predominantly involve the immunoglobulin heavy chain (IGH) locus, leading to overexpression of the full-length protein; 3 in contrast, the rare non-IG rearrangements of FOXP1 generate N-truncated isoforms that are believed to drive disease progression rather than initiation. 4 Most FOXP1-expressing lymphomas exhibit no apparent structural aberrations of the gene; 5 the short, putatively oncogenic isoforms in particular are highly expressed from the wild type locus in ABC DLBCL as a consequence of "normal" Bcell activation. 6 We have shown earlier that aberrant FOXP1 expression in ABC DLBCL may alternatively also result from dysregulated post-transcriptional regulation. 7,8 FOXP1 protein levels are regulated by the microRNA miR-34a, which itself is either transcriptionally or epigenetically silenced in nodal and extranodal DLBCL. 7 Therefore, aberrant FOXP1 expression is a common feature of various types of mature B-cell lymphomas that can result from either genetic abnormalities or transcriptional or post-transcriptional dysregulation.
FOXP1 expression is a well-documented negative prognostic factor in ABC DLBCL and MZL that can be used either alone 5, [9] [10] [11] [12] or as part of a biomarker panel. 13, 14 The inferior outcome in patients with FOXP1-expressing DLBCL holds true irrespective of gains or structural aberrations at the FOXP1 genomic locus (3p14.1), 5 and for patients treated with CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone), alone or in For personal use only. on January 8, 2016. by guest www.bloodjournal.org From combination with rituximab (R-CHOP). 5, 11, 12, 15 Due to its robust clinical implications, the biology of aberrant FOXP1 expression has received increasing attention lately. The elucidation of FOXP1 target genes whose gene products may mediate the effects of FOXP1 overexpression, and the identification of potentially druggable FOXP1 target pathways is of particular interest. FOXP1 is required for normal B-cell development, first during the pro-B to pre-B cell transition where it controls VDJ recombination by regulating RAG recombinases 16 and again in the mature B-cell, where it regulates the transition from resting, naive follicular B-cell to activated germinal center (GC) B-cell. 17 Several recent reports have addressed FOXP1 target genes in lymphoma, particularly ABC DLBCL. One study showed that FOXP1-mediated repression of its direct target Huntingtin-interacting protein 1-related (HIP1R) is associated with poor survival of ABC DLBCL patients. 18 Another study demonstrated that FOXP1 suppresses apoptosis of DLBCL cells by transcriptional repression of a set of pro-apoptotic target genes, which includes the BH3-only protein BIK and several p53 regulatory proteins. 19 Here, we have combined a genome-wide search for direct FOXP1 targets using chromatin immunoprecipitation followed by next generation sequencing and RNA interference with functional screening for biologically relevant target genes to identify novel tumor suppressor proteins in FOXP1-positive DLBCL. We provide evidence that the repressed FOXP1 target sphingosine 1-phosphate receptor 2 (S1PR2) has robust tumor suppressive activity in DLBCL cells in vitro and in vivo and represents an excellent prognostic biomarker that, either alone or in combination with FOXP1 expression, accurately predicts survival of ABC DLBCL patients.
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Methods

Cell lines and cell culture-based assays
The DLBCL cell lines used were SU-DHL4, SU-DHL6, SU-DHL10, SU-DHL16 and RC-K8 of GCB DLBCL subtype and U-2932, OCI-LY3, OCI-LY10, SU-DHL2, SU-DHL5 and RIVA of ABC DLBCL subtype (see supplemental methods for a table listing cell line details).
Cell lines were maintained at 37°C, 5% CO 2 in a humidified atmosphere in RPMI or IMDM (RIVA, OCI-LY10) supplemented with 10% (OCI-LY10, RIVA, SU-DHL2 and SU-DHL5) or 20% heat-inactivated FBS and antibiotics. The AKT inhibitor MK-2206 (Selleckchem) 
Results
The hematopoietic oncoprotein FOXP1 promotes cell survival and functions as a transcriptional repressor in DLBCL
In this study, we have embarked on a global survey of genes that are (1) regulated by FOXP1 at the transcriptional level, (2) are directly bound by FOXP1 as determined by chromatin immunoprecipitation, and (3) affect proliferation and survival in cell culture models of DLBCL. We selected several cell lines for experimentation based on their FOXP1 expression; as noted previously by us and others, the strong expression of one or several FOXP1 isoforms was more commonly observed in ABC-compared to GCB-derived cell lines (supplemental Figure 1H ,I). The siRNA targeting all isoforms was generally more potent at inducing cell death than the siRNA that preferentially targets the high molecular weight isoforms ( Figure 1B Table 1 ). To examine which of the FOXP1-regulated genes are direct targets of the transcription factor, we performed chromatin immunoprecipitation (ChIP)
For personal use only. on January 8, 2016. by guest www.bloodjournal.org From with a FOXP1-specific antibody of the two FOXP1 hi (U-2932 and SU-DHL6) cell lines also used for transcriptional profiling, as well as one FOXP1 lo (SU-DHL4) and one FOXP1negative (RC-K8) cell line ( Figure 1K ). ChIP was followed by Illumina sequencing of the precipitated genomic DNA. The consensus sequence of FOXP1-bound regulatory regions that we identified by this approach was identical in both FOXP1 hi cell lines ( Figure 1L ) and very similar to a previously reported sequence. 20 FOXP1-bound regulatory regions were predominantly identified at transcription start sites (data not shown). Of all ~6000 genomic loci bound by FOXP1 (supplemental Table 2 ), roughly one third were shared by the two examined FOXP1 hi cell lines (U-2932 and SU-DHL6, Figure 1M ). The ChIP-derived information on FOXP1-bound loci was then integrated with the lists of differentially expressed genes. Of 430 genes that were dysregulated upon FOXP1-specific RNAi as determined by RNA sequencing and/or directly bound by FOXP1 as determined by ChIPsequencing (see the supplemental methods for a detailed description of criteria and cut-offs), 27 were selected for functional analysis because they had previously been mentioned in the literature in the context of cancer, tumor suppression or B-cell biology. Figure 1N shows the gene expression changes upon FOXP1 knock-down in the two cell lines as well as the fold enrichment and number of binding sites identified in FOXP1 chromatin-immunoprecipitated DNA of the 27 genes. We conclude from the combined results that FOXP1 promotes cell survival in DLBCL cell lines and regulates the expression of numerous target genes by binding to highly conserved regulatory regions.
Expression of the sphingosine-1-phosphate receptor S1PR2 is inversely correlated with FOXP1 expression in patient biopsies
1 0
We next proceeded to functionally examine the 27 identified FOXP1 targets by manipulating their expression in U-2932 cells. FOXP1 predominantly serves as a transcriptional repressor rather than an activator of target gene expression; accordingly, we identified only two transcripts whose expression decreased upon FOXP1 knock-down. siRNAs specific for these positively regulated genes failed to affect cell viability or apoptosis (supplemental Figure   2A ,B); in contrast, ten of the 25 repressed FOXP1 target genes reduced the viability of U-2932 cells by >50% upon ectopic expression, i.e. in a gain-of-function screen (Figure 2A ). This loss of viability coincided with apoptosis induction in U-2932 cells ( Figure 2B ), suggesting that the ten genes function as potential tumor suppressors in DLBCL.
To determine which of the identified pro-apoptotic FOXP1 targets exhibit expression patterns that are inversely associated with the expression of FOXP1 in patient biopsies, we took advantage of publicly accessible gene expression profiling (GEP) datasets. One of the two available GEP datasets included 496 DLBCL patients that had been recruited as part of the International DLBCL Rituximab-CHOP Consortium Program Study 14,21,22 and received R-CHOP therapy; the other cohort consisted of 350 patients enrolled in the Lymphoma/Leukemia Molecular Profiling Project, respectively, that had been treated with either CHOP or R-CHOP. 23 We were able to confirm earlier observations demonstrating that FOXP1 expression is consistently higher in ABC compared to GCB DLBCL cases in both datasets ( Figure 2C -F). To our surprise, only a few of the 10 repressed targets with proapoptotic activity identified in the combined approaches outlined above were correlated inversely with FOXP1 in terms of their transcript abundance (supplemental Figure 2C however, one candidate, the sphingosine-1-phosphate receptor 2 (S1PR2), exhibited a nearly perfect and highly significant inverse association with FOXP1 in both DLBCL cohorts ( Figure 2C -F). A similar inverse expression pattern was observed also in the subset of ABC-1 1 DLBCL-derived cell lines that we had at our disposal ( Figure 2G ). During B-cell ontogeny, FOXP1 is highly expressed in the naive B-cell, and then again in memory B-cells as judged based on publicly available gene expression profiles; 24 both phases of B-cell development are characterized by low S1PR2 expression ( Figure 2H ). In contrast, FOXP1 lo centrocytes and centroblasts exhibit de-repressed S1PR2 expression ( Figure 2H ). The combined functional and gene expression data support the conclusion that S1PR2 is repressed at the transcriptional level in DLBCL due to aberrant expression of its negative regulator FOXP1 and that the dysregulation of S1PR2 may contribute to the survival of DLBCL cells.
S1PR2 is a direct repressed target of FOXP1 with pro-apoptotic activity in DLBCL cell lines
To validate and extend our findings linking FOXP1 to S1PR2 regulation using additional cell lines and approaches, we silenced FOXP1 expression in the three before-mentioned FOXP1positive cell lines as well as the FOXP1-negative cell line RC-K8. Silencing of FOXP1 expression with the siRNA targeting all isoforms (siFOXP1.1) lead to an increase in the expression of S1PR2 by a factor of 2-4 fold as determined by qRT-PCR in the three FOXP1positive cell lines, but not the FOXP1-negative cell line ( Figure 3A -D). We next sought to confirm the ChIP-seq results by ChIP followed by qPCR (ChIP-qPCR) specific for the S1PR2 regulatory region that is bound by FOXP1. The ChIP-seq had identified two regions 2.5 and 5kb upstream of the S1PR2 transcription start site (designated "A" and "B", supplemental we restored S1PR2 expression in three cell lines that are amenable to genetic manipulation with cDNA expression constructs (one FOXP1 hi , one FOXP1 lo and one FOXP1 -) and determined the effects of this treatment on tumor cell viability and apoptosis. Ectopic S1PR2 expression was approximately in the same range as S1PR2 expression resulting from FOXP1 depletion by RNAi (as assessed by qRT-PCR, data not shown), and consistently reduced the survival of all examined cell lines ( Figure 3I ). The loss of viability correlated well with induction of apoptosis as evidenced by staining for Annexin V and active caspase-3 ( Figure   3J ,K). We next used lentiviral transduction to generate SU-DHL6 cells harboring the S1PR2 gene under doxycyclin control, in which GFP expression allows for tracking of successful transduction. GFP-positive cells were sorted to >90% purity ( Figure 3L ); the addition of doxycyclin induced S1PR2 expression in GFP-positive, but not GFP-negative cells ( Figure   3M ) and strongly reduced cell survival ( Figure 3N ), which could be attributed to apoptosis induction ( Figure 3O ). In summary, S1PR2 is a directly regulated, repressed target of FOXP1 in DLBCL cell lines that exhibits robust pro-apoptotic activity; the results suggest that the loss of S1PR2 expression likely confers a survival advantage to DLBCL cells due to protection from apoptosis.
S1PR2 signals via the small G-protein Gα13 to induce apoptosis
S1PR2 is a G protein-coupled receptor which binds the lipid signaling molecule sphingosine 1-phosphate and couples to either of two small G-proteins, Gα12 or Gα13 (encoded by GNA12 and GNA13, respectively), to activate downstream signaling events. 25 Both small G-1 3 proteins are predominantly known for their activity in regulating proliferation and migration.
To assess whether Gα12 and/or Gα13 contribute to pro-apoptotic S1PR2 signaling, we first constructed a point mutant, S1PR2 R147C, which is expressed at normal levels but lacks the ability to interact with both small G-proteins. 26 The pro-apoptotic activity of S1PR2 R147C was reduced relative to wild type S1PR2 in several cell lines, as determined by cell viability assay as well as Annexin V and active caspase-3 staining ( Figure 4A -I). Interestingly, the ectopic expression of either of the two small G-proteins phenocopied the effects of S1PR2 on viability and cell death ( Figure 4A -I). We next assessed whether either or both small Gproteins are required for S1PR2-driven cell death in SU-DHL6 cells harboring the S1PR2 gene under doxycyclin control; interestingly, the siRNA-mediated knock-down of Gα13, but not of Gα12, reversed the phenotype of inducible S1PR2 expression ( Figure 4J ,K). The silencing of ARHGEF, a Rho guanine nucleotide exchange factor (GEF) known to function downstream of both small G-proteins to activate RhoA by exchanging bound GDP for GTP, showed similar trends as Gα13 depletion, which were however not statistically significant ( Figure 4J ,K). All three siRNAs led to a depletion of their target mRNAs by 50% or more and corresponding protein by approximately 50% (supplemental Figure 4A ,B). The combined results indicate that, although both Gα12 and Gα13 can in principle transmit pro-apoptotic signals downstream of S1PR2, only Gα13 is active in the examined DLBCL cell line. This observation is consistent with Gα13, but not Gα12, co-expression with S1PR2 in centrocytes and centroblasts ( Figure 2H , Figure 4L ).
As S1PR2 signaling has been shown to inhibit AKT phosphorylation and AKT-driven migration, 26 we speculated that S1PR2 signaling might impair DLBCL cell survival by preventing AKT-mediated survival signaling. However, we found no evidence for a role of AKT in S1PR2-driven cell death, as AKT activity -as determined by its phosphorylation on and a constitutively active, myristoylated form of AKT did not reverse the consequences of S1PR2 overexpression in DLBCL cell lines ( Figure 5C ). Furthermore, an inhibitor of AKT signaling had only modest effects on the viability of DLBCL cell lines at concentrations that strongly reduced AKT autophosphorylation on serine 473, and the susceptibility of individual cell lines did not correlate with their steady state AKT activity (which is high in U-2932 and low in SU-DHL6 cells; Figure 5D , supplemental Figure 5E ,F). The combined results suggest that the survival-promoting effects of FOXP1 depend on the repression of its target S1PR2 and of downstream pro-apoptotic signaling via the small G-protein Gα13, but not on AKTdriven survival signaling.
S1PR2 is a bone fide tumor suppressor in DLBCL in vivo
To examine whether the inducible expression of S1PR2 kills DLBCL cells in vivo, we subcutaneously implanted either 10x10 6 GFP-positive (>95% pure, data not shown) ornegative SU-DHL6 cells into NSG mice, allowed palpable tumors to form, and induced transgene expression by administration of doxycyclin via the chow. S1PR2 expression could be verified in GFP-positive cells from doxycyclin recipients, but not the other two groups ( Figure 6A ); interestingly, S1PR2 expression strongly delayed tumor outgrowth in the majority of animals, as evidenced by the tumor volume and weight over time and at the study endpoint ( Figure 6B -E). Interestingly, GFP-negative cells outcompeted GFP-positive (S1PR2expressing) cells in all examined tumors exposed to doxycyclin ( Figure 6F ), despite the fact that this population constituted less than 5% of the overall population at the time of transplantation.
We next established an orthotopic/systemic model of DLBCL by subcutaneously passaging GFP-positive and -negative SU-DHL6 cells prior to their ex vivo expansion and intravenous injection into NSG mice. Cell populations were ~95% pure at injection (data not shown).
Doxycyclin was administered to one half of the recipients of GFP-positive cells and all GFPnegative cell recipients once tumor cells appeared in the circulation after 15 days of engraftment, as judged by positive staining for the human-specific leukocyte marker CD45 (data not shown). Whereas the recipients of GFP-negative cells and the recipients of GFPpositive cells not fed doxycyclin began to lose weight at 17 days post engraftment, the weight of GFP-positive cell recipients remained relatively stable until the study endpoint (20 days post engraftment; Figure 6G ,H). The overall tumor burden in both spleen and blood was highest in recipients of GFP-negative cells, and similar in recipients of GFP-positive cells irrespective of doxycyclin exposure ( Figure 6I-K) . However, as in the xenograft model, GFPnegative (doxycyclin-unresponsive) cells outcompeted GFP-positive cells in all mice on doxycyclin relative to mice not under selective pressure, increasing from only 5% of the tumor cell population at the time of injection to >30% of the population in blood and spleen at the study endpoint ( Figure 6L ,M). The combined results confirm that S1PR2 acts as a bona fide tumor suppressor in DLBCL in vivo in both subcutanous and orthotopic models of the disease, and delays or restricts tumor cell outgrowth upon inducible expression.
To confirm the tumor suppressor function of S1PR2 in another model, we generated mice that are either wild type or harbor a heterozygous deletion of the S1PR2 gene and express MYC under the control of the immunoglobulin heavy chain enhancer (Emu-MYC). Interestingly, the loss of only one S1PR2 allele was sufficient to significantly accelerate the formation of MYCdriven nodal B-cell lymphomas ( Figure 6N ); once MYC + S1PR2 +/tumors had formed (in the spleen and various lymph nodes, especially cervical, mediastinal, brachial and inguinal) they 1 6 grew with similar kinetics as MYC + S1PR2 +/+ tumors and were morphologically indistinguishable (data not shown). This model thus provides another piece of evidence for the tumor suppressive properties of S1PR2 in B-cells, and suggests that the loss of S1PR2 function is an early event in DLBC lymphomagenesis.
S1PR2 is a positive prognostic marker in DLBCL patients
To assess a possible prognostic value of S1PR2 expression, alone and in combination with Figure 7G ,H, respectively), and predominantly in the ABC subtype of DLBCL (data not shown). The likelihood of survival was particularly dismal in patients with FOXP1 hi S1PR2 lo tumors, and especially favorable in FOXP1 lo S1PR2 hi cases, and high S1PR2 expression even allowed for accurate survival prognostication of FOXP hi cases ( Figure 7G,H) . Overall, the beneficial effect of S1PR2 expression on patient survival is consistent with its strong pro-apoptotic properties in DLBCL cell lines, and provides an explanation for the robust survival advantage of DBLCL cells that is associated with FOXP1-mediated S1PR2 repression.
Discussion
In this study, we have combined ChIP-sequencing and RNA sequencing with the functional analysis of individual target genes to identify novel FOXP1-regulated tumor suppressors in DLBCL. We found all our DLBCL cell lines to depend heavily on FOXP1 expression for growth and survival, irrespective of whether they were of ABC or GCB subtype. Consistent with a previous report, 6 we found the shorter isoforms of FOXP1 to be somewhat more critical to cell survival than the full length isoforms, although our siRNAs were not entirely specific for either one or the other. Of the 27 direct FOXP1 targets uncovered by our integrative approach, ten exhibited pro-apoptotic activity upon ectopic expression and therefore represent candidates whose repression by FOXP1 is likely to contribute to FOXP1driven tumor cell survival. We focused on the repressed target S1PR2, a G-protein coupled receptor (GPCR), because its expression was strongly negatively correlated with FOXP1 expression in two large DLBCL patient cohorts. S1PR2 could be validated as a bona fide target of FOXP1 with strong pro-apoptotic activity in multiple cell lines. Ectopic expression of wild type S1PR2 kills cells of both DLBCL subtypes with equal efficiency, suggesting that loss of S1PR2 expression is a critical pathogenetic event in both GCB as well as ABC DLBCL. Indeed, the loss of S1PR2 activity in (predominantly FOXP1-negative) GCB DLBCL was recently attributed to inactivating point mutations in the S1PR2 coding sequence, which either abrogate expression of the protein, or are structurally damaging. 26 Interestingly, such mutations are almost exclusively found in GCB DLBCL and hardly ever occur in (FOXP1-positive) ABC DLBCL. 26 Earlier work had already identified numerous somatic mutations in the 5' untranslated region of S1PR2 in DLBCL, with the location and context of the mutations pointing to aberrant somatic hypermutation as the underlying mechanism. 27 Our data on FOXP1-driven S1PR2 repression imply that the conservation of two wild type S1PR2
For personal use only. on January 8, 2016. by guest www.bloodjournal.org From alleles in ABC DLBCL 26 may be due to this alternative, transcriptional mechanism of abrogating S1PR2 expression, which should relieve negative selective pressure on the S1PR2 gene.
In GCB DLBCL, the critical contribution of S1PR2 has been attributed to its dual role in confining germinal center B-cells to lymph nodes and thus preventing their recirculation and in growth inhibition; consequently, mice lacking direct downstream effectors of the S1PR2regulated signaling pathway, i.e. Gα13 or ARHGEF1, are characterized by the systemic dissemination of germinal center B-cells and their seeding and growth in distant organs. 26 Similarly, mice lacking both alleles of S1PR2 exhibit higher frequencies and greater size of spontaneously occurring germinal centers, and half of all mice develop B-cell lymphomas of GCB morphology and molecular characteristics by 1.5 to 2 years of age. 27 Here, we show that S1PR2, in addition to its role in GC B-cell confinement and growth inhibition, exerts a direct tumor suppressive function in B-cells by promoting tumor cell apoptosis: the ectopic expression of S1PR2, either upon electroporation of DLBCL cell lines with cDNA expression constructs or upon doxycyclin-driven, inducible transgene expression from a genomic locus, rapidly induces tumor B-cell death in vitro and in vivo. Inducible S1PR2 expression alone is sufficient to strongly delay tumor development in vivo in a subcutaneous xenograft model.
Additional results obtained using a novel systemic model of DLBCL engraftment and growth in the spleen and blood lend further support to the notion that S1PR2 functions as a general pro-apoptotic tumor suppressor in B-cells. Apoptosis induction by S1PR2 involves its downstream mediator Gα13, as a mutant incapable of interacting with this small G-protein fails to trigger cell death, the ectopic expression of Gα13 (and also of the closely related Gα12) phenocopies the effects of ectopic S1PR2 expression, and the depletion of Gα13 rescues the pro-apoptotic effects of ectopic S1PR2 expression. Whereas the receptor-proximal 1 9 signaling events via small G-proteins thus promote both germinal center confinement 26 and tumor cell apoptosis as shown here, we could not find evidence for a role of AKT inhibition in S1PR2-driven tumor cell death. Several lines of evidence indicate that, while most DLBCL cell lines are modestly sensitive to AKT inhibitors, this may represent an off target effect as sensitivity is not correlated with active AKT signaling. Furthermore, the ectopic expression of constitutively active, myristoylated AKT fails to rescue DLBCL cells from S1PR2-driven apoptosis, as would be expected if AKT-driven signaling were critical to cell survival. In conclusion, although the receptor-proximal signaling events, as well as the biological consequences of S1PR2 expression on cell survival have now been elucidated in detail, the exact mechanism of apoptosis induction remains elusive. More work will be required to clarify the link between this GPCR, caspase activation and apoptosis.
Aside from the implications of the newly identified FOXP1 target genes for DLBCL pathogenesis, our findings are also of interest with regard to normal GC B-cell function. We propose that the regulation of S1PR2 as well as of activation-induced cytidine deaminase (AID) by FOXP1, which we picked up in our ChIP of FOXP1-bound promoters and were able to confirm by ChIP-PCR and RNA sequencing after FOXP1 knock-down (data not shown), accounts for the negative regulatory effects of FOXP1 on the germinal center reaction.
FOXP1 downregulation in GC B-cells on the one hand allows for S1PR2 re-expression, GC retention and negative selection of GC B-cells, and on the other hand promotes re-expression of AID and AID-induced class switching. We propose a model in which the downregulation of FOXP1 and subsequent de-repression of S1PR2 and AID promote various key properties of GC B-cells such as class switching, the ability to undergo apoptosis and allow for negative selection, and confinement to the GC area of the lymph node (see model in supplemental Figure 6 ). In summary, S1PR2 is a biologically relevant target of FOXP1 under physiological 1  7  .  S  a  g  a  r  d  o  y  A  ,  M  a  r  t  i  n  e  z  -F  e  r  r  a  n  d  i  s  J  I  ,  R  o  a  S  ,  e  t  a  l  .  D  o  w  n  r  e  g  u  l  a  t  i  o  n  o  f  F  O  X  P  1  i  s  r  eu  i  r  e  d  d  u  r  i  n  g  g  e  r  m  i  n  a  l  c  e  n  t  e  r  B  -c  e  l  l  f  u  n  c  t  i  o  n  .   B  l  o  o  d   .  2  0  1  3  ;  1  2  1  (  2  1  )  :  4  3  1  1  -4  3  2  0  .  1  8  .  W  o  n  g  K  K  ,  G  a  s  c  o  y  n  e  D  M  ,  B  r  o  w  n  P  J  ,  e  t  a  l  .  R  e  c  i  p  r  o  c  a  l  e  x  p  r  e  s  s  i  o  n  o  f  t  h  e  e  n  d  o  c  y  t  i  c  p  r  o  t  e  i  n  H  I  P  1  R  a  n  d  i  t  s  r  e  p  r  e  s  s  o  r  F  O  X  P  1  p  r  e  d  i  c  t  s  o  u  t  c  o  m  e  i  n  R  -C  H  O  P  -t  r  e  a  t  e  d  d  i  f  f  u  s  e  l  a  r  g  e  B  -c  e  l  l  l  y  m  p  h  o For personal use only. on January 8, 2016. by guest www.bloodjournal.org From and apoptosis of the three indicated DLBCL cell lines 48h post transfection with an S1PR2 expression plasmid or empty vector. Cell viability was assessed using Cell Titer Blue (I) and apoptosis was assessed using Annexin V (J) or cleaved caspase-3 staining (K) . Data represent means + SEM of at least 3 independent experiments. (L) A representative eGFP histogram of SU-DHL6 cells after infection with virus particles harboring pIND21-S1PR2. (M-O) S1PR2 expression was induced for 72h with doxycyclin in SU-DHL6 cells transduced with pIND21-S1PR2 prior to the assessment of S1PR2 transcript levels (M), as well as viability and apoptosis by Cell Titer Blue assay and Annexin V staining (N,O); data of 3 independent experiments are shown as means + SEM. * P < .05, ** P < .01, *** P < .001 calculated using two-tailed students t-test. Data are represented as means + SEM of at least 3 independent experiments. Note that roughly equal expression of the four constructs was verified using FLAG-tagged versions of the proteins (data not shown). (J,K) Viability and apoptosis of SU-DHL6 cells that inducibly express S1PR2, 72h post transfection with the indicated siRNAs; transfected cells were additionally exposed to doxycyclin for the last 48h of the experiment where indicated. Cell viability was assessed using Cell Titer Blue assay (J); apoptosis was assessed by V staining (K) . Data represent means +SEM of 3 independent experiments. * P < .05, ** P < .01, *** P < .001 calculated using two-tailed students t-test. (L) Expression levels of Gα12 and Gα13 during B-cell development, as determined using publicly available data from Genomicscape. 24 For personal use only. on January 8, 2016. by guest www.bloodjournal.org From For personal use only. on January 8, 2016. by guest www.bloodjournal.org From For personal use only. on January 8, 2016. by guest www.bloodjournal.org From
